Sensus Healthcare manufactures superficial radiation therapy (SRT) systems, proprietary low-energy X-ray devices used to treat non-melanoma skin cancers and keloid scars in dermatology and radiation oncology settings. The company generates revenue from device sales, service contracts and maintenance programs, consumable supplies, and recurring revenue-sharing agreements under which it provides both equipment and clinical staffing to medical facilities. Sensus markets its SRT-100, SRT-100 Vision, and SRT-100+ product lines to private dermatology practices and radiation oncologists, who prefer the non-invasive, surgery-free approach for sensitive facial areas and as an alternative to more complex equipment, supported by cloud-based software, financing options, and global regulatory clearances across multiple markets.